ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS with or without papillary tumors. FDA interactions centered on updated ...
Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, ...
Allegheny Health Network Department of Urology is offering a gemcitabine intravesical system to provide the therapy for BCG-unresponsive NMIBC. Ongoing shortages of Bacillus Calmette-Guérin (BCG) and ...
Morning Overview on MSN
The FDA approved Anktiva as the first treatment for one BCG-resistant form of bladder cancer
On October 14, the U.S. Food and Drug Administration announced that Anktiva (nogapendekin alfa inbakicept-pmln), used ...
An experimental treatment method has shown promise in fighting a hard-to-treat form of bladder cancer known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). BCG (Bacillus ...
(NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA ® (nogapendekin alfa ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A new review explains why BCG immunotherapy fails in some bladder cancer patients and outlines emerging combination ...
Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease. For ...
ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing authorization in the EU for ANKTIVA ® ...
WASHINGTON -- More than half of patients with previously treated non-muscle invasive bladder cancer (NMIBC) had complete responses (CRs) with an intravesical gene therapy, according to preliminary ...
The FDA extended Anktiva to high-grade papillary-only bladder cancer that no longer responds to BCG. Its reasoning rests on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results